These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 18978068)
1. Immunosuppressive therapy and post-transplant malignancy. Domhan S; Zeier M; Abdollahi A Nephrol Dial Transplant; 2009 Apr; 24(4):1097-103. PubMed ID: 18978068 [No Abstract] [Full Text] [Related]
2. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety. Huggins A; Sergott RC Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305 [No Abstract] [Full Text] [Related]
3. Fingolimod for multiple sclerosis. Pelletier D; Hafler DA N Engl J Med; 2012 Jan; 366(4):339-47. PubMed ID: 22276823 [No Abstract] [Full Text] [Related]
4. [Molecular action mechanisms of the therapeutic agents for kidney diseases: Immunosuppressants]. Nishikido M; Kanekake H; Harada T Nihon Rinsho; 2006 Feb; 64 Suppl 2():634-8. PubMed ID: 16523968 [No Abstract] [Full Text] [Related]
5. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. Massberg S; von Andrian UH N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715 [No Abstract] [Full Text] [Related]